Immediate Impact
1 by Nobel laureates 58 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
Works of Nicolas Frances being referenced
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
2018
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Nicolas Frances | 186 | 63 | 51 | 217 | 77 | 22 | 426 | |
| Lena Tran | 201 | 29 | 185 | 126 | 50 | 18 | 406 | |
| Chabner Ba | 236 | 20 | 56 | 130 | 70 | 21 | 476 | |
| Hongling Zhang | 159 | 68 | 137 | 189 | 21 | 21 | 500 | |
| Adekemi Taylor | 137 | 18 | 97 | 332 | 52 | 16 | 470 | |
| Marco Calvaruso | 74 | 24 | 72 | 154 | 59 | 23 | 423 | |
| K. Arnold | 217 | 46 | 55 | 161 | 23 | 23 | 439 | |
| Giovanni Crisafulli | 165 | 13 | 111 | 167 | 47 | 28 | 450 | |
| Evangelia Peponi | 86 | 59 | 153 | 145 | 54 | 20 | 442 | |
| K Adams | 131 | 150 | 105 | 132 | 19 | 14 | 427 | |
| Erica C. Nakajima | 232 | 53 | 187 | 223 | 25 | 21 | 496 |
All Works
Loading papers...